ArticleImmunity & ageing : I & A2025
Algorithms for appropriate patient stratification in the face of a new SARS-CoV-2 pandemic.
Article in Immunity & ageing : I & A, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the SARS-Cov-2 pandemic has passed, the virus continues to cause infection and death. Immunological response is crucial to overcome the disease. Elucidating the prognostic value of measurable immunological variables at the time of admission and throughout the disease progression could provide stratification tools, improving the management of patients.
methodsA total of 1,096 samples belonging to 979 hospitalised patients molecularly diagnosed with SARS-CoV-2 infection, together with their medical records were retrospectively analysed. Demographic data, including age, sex, date of symptom onset and admission and T, B and NK cells and serum cytokine levels, were collected as predictor variables. Stratification of patients was performed according to their severity (grade 1: uncomplicated disease; grade 2: mild pneumonia; grade 3: severe pneumonia), their admission to Intensive Care Unit and their final outcome (death vs. alive).
resultsOn admission, more severe patients were older, had lower lymphocyte subpopulation counts and higher levels of IL-6, IL-8, IL-10 and IP-10. The trend of lymphocyte counts throughout the disease progression since the symptom onset was to increase both in less and severe patients (even though in these last the levels remained significantly lower), except for NK cells, which decreased. Regarding cytokine levels, IL-6 and IL-8 tended to increase, whereas IL-10 and IP-10 tended to decrease in more severe patients, although particularly IL-10 remained significantly higher in them as compared with less severe patients, and, interestingly, its tendency was to increase in those who died. When considering the clinical evolution, an increase of IL-8 serum levels and a decrease of NK cells were significantly associated with a worsening, while an increase of CD19+ B and CD8+ T cells and a decrease of IL-6, IL-10, MCP-1 and IP-10 cytokine circulating levels were significantly related to an improvement. By integrating all the results, 13 optimal classification trees were constructed using evolutionary algorithms to predict COVID-19 outcome.
conclusionsThe age and the study of lymphocyte populations in a county hospital, together with cytokine serum level quantitation in a third-level hospital, are enough variables to predict the outcome of patients hospitalised due to SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.